First-line therapy for metastatic squamous cell carcinoma of the head and neck (R/M HNSCC) has been revolutionized by the introduction of anti-checkpoint monoclonal antibodies, which have shown a significant improvement in overall survival (OS) gaining approval in a first line setting. Efficacy and safety of first-line weekly chemotherapy, compared to 3-weeks treatment, was retrospectively evaluated in a frail patient population with R/M HNSCC with the aim to evaluate its role as part of a personalized first-line approach.

Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era / Botticelli, Andrea; Pomati, Giulia; Cirillo, Alessio; Mammone, Giulia; Ciurluini, Fabio; Cerbelli, Bruna; Sciattella, Paolo; Ralli, Massimo; Romeo, Umberto; De Felice, Francesca; Catalano, Carlo; Vullo, Francesco; Della Monaca, Marco; Amirhassankhani, Sasan; Tomao, Silverio; Valentini, Valentino; De Vincentiis, Marco; Tombolini, Vincenzo; Della Rocca, Carlo; Polimeni, Antonella; di Gioia, Cira; Corsi, Alessandro; D'Amati, Giulia; Mezi, Silvia; Marchetti, Paolo. - In: JOURNAL OF TRANSLATIONAL MEDICINE. - ISSN 1479-5876. - 19:1(2021). [10.1186/s12967-021-02975-3]

Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era

Botticelli, Andrea
Co-primo
;
Pomati, Giulia
Co-primo
;
Cirillo, Alessio
;
Mammone, Giulia;Cerbelli, Bruna;Sciattella, Paolo;Ralli, Massimo;Romeo, Umberto;De Felice, Francesca;Catalano, Carlo;Vullo, Francesco;Della Monaca, Marco;Tomao, Silverio;Valentini, Valentino;De Vincentiis, Marco;Tombolini, Vincenzo;Della Rocca, Carlo;Polimeni, Antonella;di Gioia, Cira;Corsi, Alessandro;D'Amati, Giulia;Mezi, Silvia
Co-primo
;
Marchetti, Paolo
Co-primo
2021

Abstract

First-line therapy for metastatic squamous cell carcinoma of the head and neck (R/M HNSCC) has been revolutionized by the introduction of anti-checkpoint monoclonal antibodies, which have shown a significant improvement in overall survival (OS) gaining approval in a first line setting. Efficacy and safety of first-line weekly chemotherapy, compared to 3-weeks treatment, was retrospectively evaluated in a frail patient population with R/M HNSCC with the aim to evaluate its role as part of a personalized first-line approach.
File allegati a questo prodotto
File Dimensione Formato  
Botticelli_Weekly-chemotherapy_2021.pdf

accesso aperto

Note: https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-021-02975-3
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 776.52 kB
Formato Adobe PDF
776.52 kB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11573/1562486
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact